56 search results for: mechanism of disease

The Impact <b>of</b> Skin Dysbiosis on Atopic Dermatitis
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

Dermatology
Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.
View more
The Impact <b>of</b> Type 2 Inflammation on the Neuroimmune Axis in AD
expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Dermatology
Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.
View more
Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

Dermatology
Dr. Amy Paller shares her opinion on practical considerations for evaluating response during treatment with biologics in children with atopic dermatitis.
View more
The Implications <b>of</b> Sweat Duct Dysfunction and the Microbial Dysbiosis in AD
expert video

The Implications of Sweat Duct Dysfunction and the Microbial Dysbiosis in AD

Dermatology
Dr. Lisa Beck talks about sweat duct dysfunction and the impact of S. aureus colonization.
View more
The Role <b>of</b> Epithelial Barrier Components in AD: Insights and Implications
expert video

The Role of Epithelial Barrier Components in AD: Insights and Implications

Dermatology
Dr. Lisa Beck explains the role of epithelial barrier components and barrier disruption in AD.
View more
The Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

Dermatology
Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.
View more
Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU
expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

Dermatology
Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.
View more
IRS-ISIAN 2024 | The Importance <b>of</b> Understanding Smell Loss and Congestion in CRSwNP
expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

Rhinology
Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.
View more
Exploring Neurosensitization and Pain in Prurigo Nodularis
expert video

Exploring Neurosensitization and Pain in Prurigo Nodularis

Dermatology
Dr. Gil Yosipovitch explains that patients with PN may experience pain due to neurosensitization.
View more
AD and PN: Commonalities and Differences – A Case Study
expert video

AD and PN: Commonalities and Differences – A Case Study

Dermatology
Highlights from the WCD 2023 ADVENT symposium, analyzing case studies and linked comorbidities in relation to atopic dermatitis and prurigo nodularis.
View more
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
View more
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

Dermatology
In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: LebanonChange country/region